hiv-1

Documents about hiv-1

• A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells#373662ClinicalTrials.gov
• A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3#966461ClinicalTrials.gov
• Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses.#170677NCBI PubMed Central
• A tissue-intrinsic mechanism sensitizes HIV-1 particles for TLR-triggered innate immune responses.#172050NCBI PubMed Central
• A Divergent TaqMan RT-qPCR Strategy for Isoform-Resolved Detection of HIV-1 Circular RNAs.#236143NCBI PubMed Central
• High-resolution HIV-1 m6A epitranscriptome reveals isoform-dependent methylation clusters and unique 2-LTR transcript modifications#294548HAL (France)
• Prolonged seroconversion in an elite controller of HIV-1 infection#402070DataCite
• Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults#857583ClinicalTrials.gov
• The Role of Human Ubc9 During the Human Immunodeficiency Virus Replication Cycle#982847DigitalCommons@University of Nebraska
• Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection#829648ClinicalTrials.gov
• SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir#856693ClinicalTrials.gov
• Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses#897048ClinicalTrials.gov
• Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)#872401ClinicalTrials.gov
• The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants#894286ClinicalTrials.gov
• Role of ARP2/3 mediated branched actin in HIV-1 assembly and release from infected CD4+T lymphocytes#235061HAL (France)
• Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen#892040ClinicalTrials.gov
• Project 1 Title: Body Mass Index and the Risk of HIV Acquisition in Transgender Women and Men who have sex with Men: A Secondary Analysis; Project 2 Title: Global Prevalence of Metabolic Syndrome in Adolescents Living with HIV by Protease inhibitor Exposure: A Systematic review and Meta-analysis#167692Harvard DASH
• Cancer burden and risk factors among women with HIV: a multi-regional study from the D:A:D and RESPOND cohort collaborations#14340HAL (France)
• A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules#283082ClinicalTrials.gov
• A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose#346991ClinicalTrials.gov
• A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children#880514ClinicalTrials.gov
• Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors#7903HAL (France)
• Metabolic reprogramming of CD4⁺ T cells by Zaprinast induces HIV-1 latency reversal ex vivo#284298HAL (France)
• Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects#346983ClinicalTrials.gov
• Cryoelectron tomography of HIV-1 cell-cell transmission conjugates reveals a secluded environment for viral assembly and transfer#359664bioRxiv / medRxiv
• Problems With Immune Recovery in the Gut Tissue#802231ClinicalTrials.gov
• The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis#907351ClinicalTrials.gov
• A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1#885412ClinicalTrials.gov
• ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection#905895ClinicalTrials.gov
• Safety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial#7595HAL (France)
• A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells#377268ClinicalTrials.gov
• Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection#858722ClinicalTrials.gov
• Prevention of HIV-1 Infection with Early Antiretroviral Therapy#7151OpenAlex
• Synthesis and Anti-HIV Evaluation of 3′-Triazolo Nucleosides#7951HAL (France)
• Role of histone modification on transcriptional regulation and HIV-1 gene expression: possible mechanisms of periodontal diseases in AIDS progression#70108J-STAGE (Japan)
• Investigation of the Inhibitory Effect of Some Secondary Metabolites to HIV-1 Capsid Protein Oligomerization#195237İzmir Yüksek Teknoloji Enstitüsü
• Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers#326644MIT Open Scholarship
• Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection#405370DataCite
• A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States#802365ClinicalTrials.gov
• Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance#856355ClinicalTrials.gov
• External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA#867213ClinicalTrials.gov
• Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa#879226ClinicalTrials.gov
• HIV/STD Safer Sex Skills Groups for Women in Drug Treatment Programs - 1#1032067ClinicalTrials.gov
• Evaluating the role of PLGF and VEGFR-1/ Flt-1 in the development of cervical intraepithelial neoplasia and invasive cervical carcinoma in the background of HIV infection in women living in South Africa#431826SUNScholar
• Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection#609404eScholarship
• Longitudinal imaging of HIV-1 spread in humanized mice with parallel 3D immunofluorescence and electron tomography#784379eScholarship
• Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment#1045204ClinicalTrials.gov
• A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies#346972ClinicalTrials.gov
• A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children#879871ClinicalTrials.gov
• Propriétés génotypiques et phénotypiques des glycoprotéines d'enveloppe de VIH-1 utilisant CXCR4 chez les personnes récemment infectées#391897HAL (France)